{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T06:46:47Z","timestamp":1768718807005,"version":"3.49.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,12]],"date-time":"2022-02-12T00:00:00Z","timestamp":1644624000000},"content-version":"am","delay-in-days":376,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015691","name":"Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.vaccine.2020.12.023","type":"journal-article","created":{"date-parts":[[2021,1,22]],"date-time":"2021-01-22T08:47:50Z","timestamp":1611305270000},"page":"1195-1200","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0373-4643","authenticated-orcid":false,"given":"DeAnna J.","family":"Friedman-Klabanoff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea A.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Travassos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingjun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie X.","family":"Mo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Effie Y.H.","family":"Nomicos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory A.","family":"Deye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcela F.","family":"Pasetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3874-581X","authenticated-orcid":false,"given":"Matthew B.","family":"Laurens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.12.023_b0005","series-title":"World malaria report 2019","author":"World Health Organization","year":"2019"},{"key":"10.1016\/j.vaccine.2020.12.023_b0010","doi-asserted-by":"crossref","first-page":"7092","DOI":"10.1074\/jbc.M106862200","article-title":"Binding and invasion of liver cells by Plasmodium falciparum sporozoites. Essential involvement of the amino terminus of circumsporozoite protein","volume":"277","author":"Rathore","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.vaccine.2020.12.023_b0015","article-title":"Efficacy and safety of the RTS, S\/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites","volume":"11","author":"RTSS Clinical Trials Partnership","year":"2014","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2020.12.023_b0020","first-page":"31","article-title":"Efficacy and safety of RTS, S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial","volume":"6736","author":"RTSS Clinical Trials Partnership","year":"2015","journal-title":"The Lancet"},{"key":"10.1016\/j.vaccine.2020.12.023_b0025","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/S1473-3099(15)00239-X","article-title":"Immunogenicity of the RTS, S\/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial","volume":"15","author":"White","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2020.12.023_b0030","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nm.4512","article-title":"A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite","volume":"24","author":"Kisalu","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2020.12.023_b0035","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nm.4513","article-title":"A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein","volume":"24","author":"Tan","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2020.12.023_b0040","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0107764","article-title":"A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate","volume":"9","author":"Noe","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.12.023_b0045","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/infdis\/jiv154","article-title":"Proteolytic Cleavage of the Plasmodium falciparum Circumsporozoite Protein Is a Target of Protective Antibodies","volume":"212","author":"Espinosa","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.12.023_b0050","doi-asserted-by":"crossref","first-page":"5721","DOI":"10.1128\/IAI.00591-08","article-title":"Low prevalence of antibodies to preerythrocytic but not blood-stage Plasmodium falciparum antigens in an area of unstable malaria transmission compared to prevalence in an area of stable malaria transmission","volume":"76","author":"Noland","year":"2008","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2020.12.023_b0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016333","article-title":"Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant","volume":"6","author":"Coler","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.12.023_b0060","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/978-1-4615-1823-5_22","article-title":"Structural and immunological characterization of the vaccine adjuvant QS-21","volume":"6","author":"Kensil","year":"1995","journal-title":"Pharm Biotechnol"},{"key":"10.1016\/j.vaccine.2020.12.023_b0065","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1093\/cid\/ciy1140","article-title":"First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria","volume":"69","author":"Mordmuller","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2020.12.023_b0070","unstructured":"Venkatraman N, Tiono A, Bowyer G, et al. Phase I assessments of first-in-human administration of a novel malaria anti-sporozoite vaccine candidate, R21 in matrix-M adjuvant, in UK and Burkinabe volunteers. In: American Society of Tropical Medicine and Hygiene Annual Meeting. (National Harbor, Maryland, USA)."},{"key":"10.1016\/j.vaccine.2020.12.023_b0075","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/infdis\/jiaa421","article-title":"A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS, S\/AS01E and RTS, S\/AS01B Delayed Fractional Dose Regimens in Malaria-Naive Adults","volume":"222","author":"Moon","year":"2020","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20315905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20315905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:52:54Z","timestamp":1759402374000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20315905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S0264410X20315905"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.12.023","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low dose recombinant full-length circumsporozoite protein-based Plasmodium falciparum vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.12.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}